Icon Legend

This session is not on your agenda.

This session is on your agenda. Click again to remove it.

Presentation Icons

ACVIM Resident Research Award Eligible

Additional Fees May Be Required

By Invite Only

Capturing for On Demand

Cardiology Research Abstract Award Eligible

ERC Approved Lecture for ACVIM Residency

Poster

Livestream

One Health

Pre-Registration Required

Research Abstract

Specialty Symposium

ACVIM Resident Research Award Winner

Cardiology Research Abstract Award Winner

Back

15 Views

ViewAttendees 1

Technician

Neurology

Oncology

Meningoencephalitis of Unknown Origin and Cytarabine Treatment

Friday, June 20, 2025

4:30 PM – 5:30 PM ET

Pending CE: 1.0 Medical

Sponsored by

Primary Presenter(s)

Danielle DeCormier, LVT, VTS (Oncology), CFE

Director, Clinical Services Education
MedVet
Whitmore Lake, Michigan, United States

Co-Presenter(s)

MC

Melissa Campo, BS, MSc, CVT, VTS (Neurology)

BluePearl
Northfield, Illinois, United States

Disclosure(s):

Danielle DeCormier, LVT, VTS (Oncology), CFE: No financial relationships to disclose

Discover the world of Meningoencephalitis of Unknown Origin (MUO) in this lecture, as we look at how this condition presents in veterinary patients. We will delve into the clinical manifestations, explore potential causative factors, and treatments, primarily focusing on cytarabine. This presentation will offer insight into cytarabine’s mechanisms of action in resolving inflammation and restoring neurological function, despite being chemotherapy.

Learning Objectives:

By the end of this lecture, participants will be able to identify and describe the diverse clinical manifestations of Meningoencephalitis of Unknown Origin (MUO) in veterinary patients, gaining a comprehensive understanding of the wide range of neurological symptoms associated with this condition.
After attending this lecture, learners will be able to analyze potential causative factors contributing to MUO in veterinary patients, and evaluate the treatment options.
By the conclusion of this presentation, attendees will have a clear grasp of the mechanisms through which cytarabine exerts its effects, particularly in the context of alleviating inflammation and facilitating neurological recovery in cases of MUO. Participants will be able to appreciate the multifaceted role of chemotherapy agents in veterinary medicine beyond their conventional applications.